Treatment News : 99% Cure Rates for AbbVie’s Hep C Combo in Genotype 1b

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » March 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


March 6, 2014

99% Cure Rates for AbbVie’s Hep C Combo in Genotype 1b

CROI 2014AbbVie’s investigational triple-combination therapy cured close to 100 percent of people with genotype 1b of hepatitis C virus (HCV) in a large Phase III trial, MedPage Today reports. K. Rajender Reddy, MD, of the University of Pennsylvania presented findings from the PEARL-III trial at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

The results position AbbVie in a competitive position against Gilead Sciences’ combination pill of Sovaldi (sofosbuvir) and its investigational drug ledipasvir, which has had similarly stellar results in clinical trials. Gilead filed for approval for that combination therapy on February 19. Some have theorized that AbbVie may attempt to undercut Gilead on price, leading insurers to overlook the raised pill burden of AbbVie’s option if it works as well as Gilead’s therapy.

The AbbVie trial included 419 participants who received 12 weeks, with or without ribavirin, of the so-called “three-D” therapy: the ritonavir-boosted protease inhibitor ABT-450/r (a coformulated pill of the two drugs), the NS5A inhibitor ABT-267 and the non-nucleoside NS5B inhibitor ABT-333.

A total of 99.5 percent of those who took ribavirin and 99 percent of those who did not achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure). The researchers concluded that ribavirin offered no treatment advantage.

Of the just three people who did not achieve an SVR12, two were lost to follow-up and one developed a resistance mutation during treatment and experienced virologic failure.

The major adverse side effects were headache, fatigue, itching, nausea and weakness. The rates of the latter two side effects were significantly greater among those taking ribavirin.

To read the MedPage Today story, click here.

Search: AbbVie, three-D, K. Rajender Reddy, University of Pennsylvania, Conference on Retroviruses and Opportunistic Infections, Gilead Sciences, Sovaldi, sofosbuvir, ledipasvir, ritonavir, ABT-450/r, ABR-267, ABT-333.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.